SIM0711

SIM0711 is a potent and selective oral proteolysis-targeting chimera (PROTAC) designed to degrade Interleukin-1 receptor-associated kinase 4 (IRAK4). Developed by Simcere Pharmaceutical Group, SIM0711 targets both the kinase activity and the scaffolding function of IRAK4, which is a critical mediator in innate immune signaling downstream of Toll-like receptors (TLRs) and the IL-1 receptor (IL-1R). By degrading the entire protein rather than just inhibiting its kinase activity, SIM0711 aims to achieve more comprehensive pathway inhibition compared to traditional small molecule inhibitors. Preclinical studies have demonstrated its ability to induce near-complete IRAK4 degradation in human immune cells and stromal cell lines, leading to significant reduction in pro-inflammatory cytokines such as IL-6 and IL-8. It has shown efficacy in mouse models of skin inflammation and is being developed for the treatment of various autoimmune and inflammatory diseases.